

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **GENOR BIOPHARMA HOLDINGS LIMITED**

**嘉和生物藥業（開曼）控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6998)**

### **VOLUNTARY ANNOUNCEMENT LAUNCH OF PHASE I/II CLINICAL TRIAL OF GB261 IN CHINA**

The announcement is made by Genor Biopharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce today that the first patient has been dosed in the Phase I/II clinical trial of GB261 (CD20/CD3, bispecific antibody) in China. The clinical trial application was approved by the National Medical Products Administration (NMPA) on 23 May 2022 for the treatment of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (B-NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The trial then achieved first patient dosed in China on 8 September 2022.

GB261 is a novel and innovative CD20/CD3 bispecific antibody. Dose escalation of GB261 is in progress in the first-in-human clinical trial in Australia, and GB261 has demonstrated preliminary clinical efficacy, good safety and pharmacokinetic profile.

#### **About GB261 (CD20/CD3, BsAb)**

GB261 is the first T-Cell Engager with ultra-low affinity to bind CD3 and has Fc functions (ADCC and CDC). GB261 significantly inhibits rituximab-resistant cancer cell proliferation in both in vitro assays and in vivo models. With T-cell activation, GB261 also induces less cytokine release compared with compound in the same class. Thus, GB261 is a highly promising bispecific therapeutic antibody for B cell malignancies. It has potential to be a better and safer T-cell engager with competitive advantages over other CD3/CD20 agents.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that it will be able to develop, or ultimately market GB261 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board  
**Genor Biopharma Holdings Limited**  
**Dr. Guo Feng**  
*Chief Executive Officer and Chairman*

Hong Kong, 8 September 2022

*As at the date of this announcement, the Board comprises Dr. GUO Feng (Chief Executive Officer and Chairman) as an executive director; Dr. LYU Dong, Mr. CHEN Yu and Mr. LIU Yi as non-executive directors; Mr. ZHOU Honghao, Mr. FUNG Edwin and Mr. CHEN Wen as independent non-executive directors.*